Abstract
Introduction

Although the results of adult and embryonic stem cell therapy for the infracted myocardium have yielded promising results for the enhanced regeneration of myocardial tissue leading to improved ventricular function [1-3], the effectiveness of stem cell therapy is often blurred from the non-survival of the stem cells due to the oxidative stress in the normal tissue [4]. In recent years, several attempts have been made for the enhancement of the survival and proliferation of stem cells in conjunction with the stem cell therapy. Overexpression of cardiac survival protein Pim-1 in cardiac progenitor cells (CPCs) has yielded promising results as demonstrated by the enhanced proliferation and functional improvement relative to control progenitor cells after myocardial infarction
. In another study, intramyocardial injection of hepatocyte growth factor stimulated resident CPCs and potentiated cardiomyocyte regeneration after myocardial infarction by promoting the proliferation and survival of CPCs [6] . Another related study with lipopolysaccharide preconditioning of mesenchymal stem cells before the transplantation surgery, resulted in superior neovascularization resulting in the recovery of cardiac function [7] . Simvastatin 
Regeneration of myocardium 28 days after myocardial infarction
Cellular proliferation was studied by the expression of Ki67 28 days after LAD occlusion, and our results show that Ki67 staining was remarkably increased in resveratrol-treated myocardium compared to control hearts (Table 1). Cardiac regeneration was studied by staining the cardiac tissue section with GFP. Quantification of GFP staining 28 days after LAD occlusion indicate that GFP staining was remarkably increased in resveratrol-treated myocardium compared to control hearts. Confocal microscopic images showed the significant enhancement of c-kit ϩ cells 28 days after myocardial infarction in resver-
atrol-treated samples (Fig. 1A) , and the co-expression of SDF-1 and GFP in resveratrol-treated hearts (Fig. 1B) leading to the regeneration of the myocardium in the resveratrol-treated heart (Fig. 1C) . [13] . reduced environment [12] . We also selected this compound because of its well-known ability to enhance the antioxidant defence mechanism [12] . Our results revealed for the first time that it is possible to maintain a safer niche for the stem cells with proper nutrition, which could result in enhanced proliferation, myocardial regeneration and differentiation leading to an improved cardiac function. To achieve this, we pre-treated the rats with resveratrol, in a pre-determined dosage of 2.5 mg/kg/day [11] . Resveratrol has the potential to donate hydrogen or react with superoxide anion, hydroxyl radicals and lipid peroxyl radicals [14] , and has been shown to modulate antioxidant enzymes involved in the phase II response such as haem oxygenase 1 [15] . Furthermore, resveratrol has been shown to increase plasma antioxidant capacity and decrease lipid peroxidation in vivo [16] . In vitro studies show that resveratrol prevents myocardial infarction by chelating metal ions as well as by directly scavenging free radicals [17] . Resveratrol induces the activities of catalase and quinone reductase 1 and reduces the amount of reactive oxygen species (ROS) generated by menadione in the myocardium of guinea pigs [18] . [19] . Nrf2 plays a critical role in the protection of the murine heart against pathological cardiac hypertrophy and heart failure via suppressing oxidative stress [20] Nrf2 mediated adaptive response has been shown to protect against superoxide anion-induced oxidative damage [21] and cadmium-induced oxidative stress in mouse embryonic fibroblasts [22] . 
M-mode echocardiogram of rats recorded at 28 days after survival surgery reveal that resveratrol treatment enhanced the cardiac stem cell-mediated improvement in cardiac functional parameters such as LVID in systole, EF, LVID in diastole, FS and CO (Table 2).
Concluding remarks
Despite the cell-based therapy for cardiac diseases has yielded promising results for the improvement of cardiac function and regeneration, the stems cells fail to survive for a prolonged time for several factors including the persistence of oxidative environment in the target tissue. In clinical trials for the treatment of acute and chronic myocardial ischemia, a variety of progenitor cells including bone marrow-derived progenitor cells, bone marrowderived mononuclear circulating progenitor cells, as well as skeletal myoblasts have been used
